← Back to Clinical Trials
Recruiting Phase 4 NCT07022496

NCT07022496 Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07022496
Status Recruiting
Phase Phase 4
Sponsor Ain Shams University
Condition Migraine
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2023-04-26
Primary Completion 2025-07

Trial Parameters

Condition Migraine
Sponsor Ain Shams University
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 120
Sex ALL
Min Age 18 Years
Max Age 60 Years
Start Date 2023-04-26
Completion 2025-07
Interventions
Caffeine (200 mg)triptansNSAID (Nonsteroidal anti-inflammatory drugs)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Caffeine extracted from green tea to abort acute attack of Migraine

Eligibility Criteria

Inclusion Criteria: Patients suffering from migraine with aura, migraine without aura, episodic, and chronic migraine according to ICHD-3 diagnosis will be legible for the study. Exclusion Criteria: Patients who have history of any cardiac dysrhythmia, hypertension, ischemic heart disease, active peptic ulcer disease, inflammatory bowel disease, obsessive compulsive disorder, pregnancy, breast-feeding, renal failure, hepatic failure, sleep disorder, mental retardation, and history of substance abuse that prevent them from cooperating with us during the study Patients who had headache due to: Cluster headache, trigeminal neuralgia, glossopharyngeal neuralgia, headache secondary to trauma, cranial disorder, vascular disorder, infection, or mass lesion, will also be excluded

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology